text:
Recognize importance of trees
Going Nature's Way
I am a tree hugger — literally and philosophically. Maybe it began in grade school after having to memorize the poem "Trees," by Joyce Kilmer. It begins, "I think that I shall never see; A poem lovely as a tree." When I was a child trees were a source of endless challenge and fun, as climbing them became a regular pursuit. Even today I look at the lower branches of trees when hiking and analyze their suitability for climbing. I admit that occasionally I have tested a few, but with age comes a greater sense of our vulnerability and mortality and I stay on the lower branches.
Trees are vulnerable, too. That was very obvious after the last storm when straight line winds toppled, broke or uprooted large, stately trees that had sheltered many a home for decades. The saturated soil, along with the power of the wind was too much for many of these elders. Some fell on houses and garages, others flattened parked cars. Regardless of where they fell, they left a big hole in people's lives. We take our trees for granted, until they are suddenly gone. It is always surprising to me how much empty space exists when a tree of any size is taken down. When it has happened in our own yard, I have always felt a sense of loss. While I do not cherish trees as I might a beloved pet, I feel them to be part of our lives.
They provide us with a place to hide from the hot summer sun, and a buffer from the winter winds. If you happen to have a slope in your yard, trees with their great, outstretched roots help hold the soil in place. They offer shelter and food to the birds that we so enjoy listening to each and every day. And the sounds of the wind moving through the leafy boughs can be a soothing night time lullaby. These are the ways we take advantage of trees living near us.
We need trees in so very many ways. You have probably heard them referred to as the lungs of the planet and so they are. While humans and all creatures in the animal kingdom exhale CO2, trees suck it up and in return, release oxygen. Over the past century, through industrialization, we have added more and more CO2 to our atmosphere, while at the same time drastically reducing the forests of the world. Not a good recipe for a healthy ecosystem. Trees not only take in CO2, they also store it in their tissue, creating a "sink" for this greenhouse gas.
And yet, I know very well that we need trees for so many other aspects of our lives. At our home we burn wood in the winter months in our cast iron stove. We sit on wooden chairs, eat on wooden tables, and sleep in wooden bed frames. We write on paper that comes from wood pulp. I know that we must and will continue to harvest trees for our needs, but I also know that our forest management must be sustainable and well planned. Too often in the past we have taken down the oldest of the old, trees that have stood for centuries and were perfectly healthy. These are the behemoths that give rise to others of their kinds and offer countless other species of animal shelter and food.
The Tongass National Forest in Alaska is currently facing some important management decisions. Although the Tongass covers nearly 17 million acres, more than half of the old growth has been cut down. Today, less than one half of one percent of the forest is made up of the giant tree stands.
Clear cutting is a practice that denudes hillsides and allows erosion to remove the irreplaceable topsoil, as well as the mature trees that can help generate new growth through their seeds. Timber companies are usually quick to replant, so that they will have a continued resource, but these trees are all the same age and species and do not provide the same services to the greater ecosystem that a diverse forest does.
We have seen in Colorado this summer what the earlier practice of removing fire from the forests has wrought. As people have moved into these areas, we naturally wanted to protect their homes and lives, but with a warming climate, insects have been able to attack and kill huge stands of conifers. The monstrous and disastrous fires that have blackened whole mountainsides were inevitable. The trees will come back, but in a dry state such as Colorado, it will be a very, very slow process.
I think a lot about the trees on our property. I revel in their summer green cloaks and the way they sway and wave in the wind, but we too live surrounded by forests and are just as vulnerable as those people in Colorado. I hold my breath each spring until things begin to green up and the fire season has passed. I watch the trees closely for signs of disease or decline. Each year we plant a few more, whether flowering crabs in the front yard or red pine seedlings along the fence line. I know I will not live long enough to see them reach great heights, but it still gives me pleasure and satisfaction to know that someone else will. Maybe even another tree hugger like myself.


text:
Morena Baccarin Short Curls
Morena Baccarin chose tight ringlet curls for her evening hairstyle at the 'Vogue' and MAC Cosmetics Dinner party in LA.
Morena Baccarin Bright Lipstick
A bright orange lip color brought out the olive in Morena's lovely skin.
Browse: Morena Baccarin | Short Curls | Bright Lipstick
Popular Lookbooks see all looks »

subset: commoncrawl


text:
November 12, 2007
LOS ANGELES - Presented as a breakthrough for executives and managers with disabilities, UCLA Anderson School of Management is launching its Leadership Institute for Managers with Disabilities on November 12-16, 2007. The five-day program, offered through the school's Office of Executive Education, will examine promotion and career advancement issues affecting these professionals, while addressing relevant leadership, and community specific topics, as well.
"This program will move the goal posts of the current employer/activist debate away from recruitment, hiring and retention of people with disabilities," said Laurie Dowling, faculty co-director of the Institute. "Instead, the dialogue will be about how to self-facilitate ones promotion as an executive with disabilities up the corporate career ramp."
Developed with leading thinkers well-versed on the experiences of persons with disabilities in the workplace, the Institute will help participants maximize their personal, professional, and organizational potential through enhanced teamwork and leadership skills. Participants will learn to think, lead, and manage in ways that celebrate their individual attributes and perspectives, while also boosting their position within their organization.
"We must have 'out and proud' disabled executives willing to distinguish themselves as role models," said John D. Kemp, executive director and general counsel to the US Business Leadership Network, a founding organization of the Institute. "This program offers an opportunity to nurture our culture of disability and protect and enhance the identity of people with disabilities at all levels of a corporation."
The Institute represents a logical and timely addition to UCLA Anderson's renowned Leadership Suite series which offer programs for African American, Latino, women, and lesbian, gay, bisexual, and transgender managers. The programs are designed to help participants maximize their personal, professional, and organizational potential, while holding fast to the principle that building a truly diverse workforce will have a positive impact on the bottom-line of any organization.
Founding organizations of the Institute include AIG, AOL, AT&T, DiversityInc, Fannie Mae, Google, IBM, Merck, Microsoft Corporation, Motorola, Office of Disability Employment Policy, PepsiCo, Society for Human Resource Management, Union Bank of California, and the U.S. Business Leadership Network. The Institute has been funded in part with federal funds from the U.S. Department of Labor, Office of Disability Employment Policy.
About UCLA Anderson Executive Education Programs
The Office of Executive Education Programs offers an array of intensive certificate programs for executives, managers and other professionals, hosting nearly 2,000 participants annually from some 50 countries. Incorporating the most recent innovations in management education, each program provides perspective on global management, leadership, and strategic thinking - invaluable tools in today's ever-changing information economy. Custom programs can also be designed to meet organizations' specific business objectives. The Office of Executive Education Programs relies heavily on UCLA Anderson's acclaimed faculty, which includes some of the most outstanding educators and researchers from the academic and business worlds.
About UCLA Anderson School of Management
UCLA Anderson School of Management, established in 1935, is regarded among the very best business schools in the world. UCLA Anderson faculty are ranked #1 in "Intellectual Capital" by BusinessWeek and are renowned for their teaching excellence and research in advancing management thinking. Each year, UCLA Anderson provides management education to more than 1,600 students enrolled in MBA, Executive MBA, Fully-Employed MBA and doctoral programs, and to more than 2,000 professional managers through executive education programs. Combining highly selective admissions, varied and innovative learning programs, and a world-wide network of 35,000 alumni, UCLA Anderson develops and prepares global leaders.


text:
When high school junior Nora Huynh got her report card, she was devastated to see that she didn't get a perfect 4.0.
Nora "had a total meltdown, cried for hours," her mother, Jennie Huynh of Alameda, Calif., says. "I couldn't believe her reaction."
Nora is doing college-level work, her mother says, but many of her friends are taking enough advanced classes to boost their grade-point averages above 4.0. "It breaks my heart to see her upset when she's doing so awesome and going above and beyond."
And the pressure is taking a physical toll, too. At age 16, Nora is tired, is increasingly irritated with her siblings and often suffers headaches, her mother says.
Parents are right to be worried about stress and their children's health, says Mary Alvord, a clinical psychologist in Maryland and public education coordinator for the American Psychological Association.
"A little stress is a good thing," Alvord says. "It can motivate students to be organized. But too much stress can backfire."
Almost 40 percent of parents say their high-schooler is experiencing a lot of stress from school, according to a new NPR poll conducted with the Robert Wood Johnson Foundation and the Harvard School of Public Health. In most cases, that stress is from academics, not social issues or bullying, the poll found. (See the full results here.)
Homework was a leading cause of stress, with 24 percent of parents saying it's an issue.
Teenagers say they're suffering, too. A survey by the American Psychological Association found that nearly half of all teens — 45 percent — said they were stressed by school pressures.
Chronic stress can cause a sense of panic and paralysis, Alvord says. The child feels stuck, which only adds to the feeling of stress.
Parents can help put the child's distress in perspective, particularly when they get into what Alvord calls catastrophic "what if" thinking: "What if I get a bad grade, then what if that means I fail the course, then I'll never get into college."
Then move beyond talking and do something about it.
That's what 16-year-old Colleen Frainey of Tualatin, Ore., did. As a sophomore last year, she was taking all advanced courses. The pressure was making her sick. "I didn't feel good, and when I didn't feel good I felt like I couldn't do my work, which would stress me out more," she says.
Mom Abigail Frainey says, "It was more than we could handle as a family."
With encouragement from her parents, Colleen dropped one of her advanced courses. The family's decision generated disbelief from other parents. "Why would I let her take the easy way out?" Abigail Frainey heard.
But she says dialing down on academics was absolutely the right decision for her child. Colleen no longer suffers headaches or stomachaches. She's still in honors courses, but the workload this year is manageable.
Even better, Colleen now has time to do things she never would have considered last year, like going out to dinner with the family on a weeknight, or going to the barn to ride her horse, Bishop.
Psychologist Alvord says a balanced life should be the goal for all families. If a child is having trouble getting things done, parents can help plan the week, deciding what's important and what's optional. "Just basic time management — that will help reduce the stress."
It's MORNING EDITION, from NPR News. I'm Renee Montagne.
And I'm Steve Inskeep. Today in Your Health, two stories looking at how school affects your child's health and well-being. They arise from the findings of a new poll NPR has conducted with the Robert Wood Johnson Foundation and the Harvard School of Public Health. In our first story, NPR's Patti Neighmond looks at one finding that stands out. More than one-third of parents with children in high school say their child is experiencing a lot of stress, mostly from homework and academic pressure.
PATTI NEIGHMOND, BYLINE: Sixteen-year-old Nora Huynh is a junior in high school and was desperate for a 4.0. She knows this is the year everyone says is the make-it-or-break-it year for college.
Nora's mother, Jennifer Huynh.
JENNIFER HUYNH: When she saw that she didn't get a 4.0 because of the B-pluses, she basically had a breakdown, and was crying for hours - literally, hours - about it.
NEIGHMOND: Many of Nora's friends have high GPAs, with honors and advanced courses boosting them to 4.5, 4.6 and higher.
HUYNH: It was just heartbreaking to see her so upset when she'd done so good, in our eyes. To be at the level that she's at already - I mean, she's doing college prep work and she's 16 years old, and she's getting B-pluses and As in that. And that's amazing to us.
NEIGHMOND: In our poll, 1 in 4 parents say their teen is stressed by the amount of homework. Nora spends two to four hours a night on hers, leaving barely enough time for anything else. The pressure is taking a toll. She's tired, easily irritated and suffers headaches.
Psychologist Mary Alvord, with the American Psychological Association, says a little stress is a good thing. It can motivate students to be organized. But too much can backfire.
MARY ALVORD: I think when it's at the extreme and too much stress, there is a certain sense of panic and paralyzation. They just feel like they can't do anything. They're just sort of stuck.
NEIGHMOND: Alvord says parents should be on the lookout for changes in behavior - irritability, upset stomachs and headaches. If your child is very upset, she says, deep breathing and visualizing a peaceful scene - like a beach - helps calm the body and mind. And parents need to put a child's distress in perspective, particularly what Alvord calls catastrophic what-if thinking.
ALVORD: If I get a bad grade, then - you know, what if that means I'll fail the course? If I fail the course, then I'll never get into college.
NEIGHMOND: Remind your child everybody isn't good at everything. Then scrutinize their schedule. Consider cutting back on extracurriculars - like sports, clubs, student council - and think about reducing the number of honors courses. That's what Colleen Frainey did. She was taking all advanced courses when she was a sophomore in high school, and it was making her sick.
COLLEEN FRAINEY: I didn't feel good. And when I didn't feel good, I felt like I couldn't do my work - which would stress me out more.
NEIGHMOND: With encouragement from her parents, Colleen did the unthinkable. She dropped one of her advanced courses. Her mom, Abigail Frainey.
ABIGAIL FRAINEY: We had heard all along that your junior year is your hardest, your junior year is your hardest. It's the most intense. And we thought, how can we handle more intensity than we did in her sophomore year? It's just not what she could handle, or we could handle as a family.
NEIGHMOND: It was a decision questioned by lots of her friends.
ABIGAIL FRAINEY: Why would I allow my daughter to not take the hardest classes? She's bright, and she's intelligent; she can do it. Why would I let her take the easy way out?
NEIGHMOND: But Frainey says it was absolutely the right decision. Colleen no longer suffers headaches or stomachaches. She's still in honors courses, but the workload this year is manageable.
ABIGAIL FRAINEY: This year compared to last year, this year is phenomenal.
NEIGHMOND: Colleen now has time to go out to dinner with her family, or ride her horse. Psychologist Alvord says a balanced life like this is the goal. And if a child is having trouble getting everything done, parents can help them plan.
ALVORD: How are we going to schedule the week? What are you going to do when? And we know, often when we just decide on a plan of action, the stress goes down.
NEIGHMOND: With school projects, help your child break them into smaller steps. Write a paragraph a night; do things ahead of time - basic time management that will help reduce the stress.
Patti Neighmond, NPR News. Transcript provided by NPR, Copyright NPR.


text:
And now here, tonight, comes this piece, which represents his BAM project. BAM stands for Book-A-Month. Each student selects a book of his or her choice based on a specified genre, reads it, writes up an "organizer" with questions, and completes some kind of written or artistic project related to the book.
This month's BAM was a historical fiction book, and Boo chose one that we have at home, Teddy Roosevelt and the Treasure of Ursa Major, by Ronald Kidd. For his project, he had to write an "interview" with the characters.
Boo chose to do his as if it was an interview segment on the local news, featuring all of the characters from the book who appeared on the news to discuss their exploits.
He's allowed me to reprint his work here, and I've left the spelling and grammar alone. So sit back, enjoy, and watch me give this teacher hell if she doesn't give my kid an A on this. Just kidding.
Live at 106 news about how Theodore Roosevelt and his kids found the Treasure of Ursa Major.
News Man: In 1901-1909, there were four kids that lived with their father, Theodore Roosevelt in the White House. There was James Roosevelt, Ethel Roosevelt, Kermit Roosevelt and the narrator of the book, Archie Roosevelt. From the cluttered study to the spooky attic, these four kids got on an exciting adventure in the White House. But the trouble coming their way was a ghost in the White House. Teddy Roosevelt and the Treasure of Ursa Major was based on a play produced by the Kennedy Center and the White House Historical Association that is touring across the country.
Archie: The Main Idea of the Text is how I (Archie) and my siblings get their hands on a treasure map, leading them to an extraordinary adventure. They also get help with the treasure hunt with a woman named Mrs. Duffit and the word "anagrams"
Kermit: the White House is where ALL of the Adventure takes place. It sometimes took place in Teddy Roosevelt's office. Or it took place in the White House hallways.
News Man: I think the story is based on this character, Archie Roosevelt. Youngest of 3-4 Roosevelt Kids. He says "Before I found the treasure of Ursa Major, I was just Kermit, Ethel and maybe James' young, useless brother.
Teddy Roosevelt: The problem of what the treasure hunt was about was that A ghost was in the white house. But Kermit, Ethel and Archie, the three bravest kids were able to find the treasure with help from me.
Kermit: I, Ethel and our younger brother Archie's favorite part of the adventure/hunt was when we found out that we found a treasure map with rhymes.
News Man: Teddy Roosevelt, nicknamed the Roughrider helped his brave little boys & girls find the treasure that they have looked the entire time for. We now go live with our star of this hunt, Archie Roosevelt.
Archie: I, Archie Roosevelt found the end of this heroic adventure to be stunning. In conclusion, before the end I, Ethel and Kermit Roosevelt were just ordinary young kids of the president. That was until we found out a ghost was in the house?
News Man: What did you think the ghost looked liked Kermit?
Kermit: If you say "You aren't afraid of ghosts", your wrong-wrong-wrong. It was so scary that Archie was asking "I gotta change my trousers" it was hilarious and frightening at the same time.
New Man: So you think that the ghost in the White House was funny and scary?
Kermit: No. Archie saying that he needed to change his trousers was funny but the ghost was terrifying.
News Man: What happened before the ghost appeared?
Archie: There was a lady named Mrs. Duffit who was I think Dad's butler or maid or someone who was really an actress in the White House but she told us that if we kept hunting for treasure there would be consequences.
Kermit: I hope that doesn't give you the Itsy Bits. Anyway, moving on to the part where we found the Ghost. We found the ghost I think in the bed of Abraham Lincoln where Lincoln wasn't there.
News Man: How can you prove that it was EXACTLY there? My viewers and audience want to know.
Teddy Roosevelt: If you don't believe in my son I'll show you. One of these pages shows one of the kids saying they found the ghost in the bed of Abraham Lincoln.
News Man: Last question but not least, what happened at the very end of the story/hunt/adventure?
Teddy Roosevelt: Mrs. Duffit proved she was an actress, Archie proves he isn't a useless younger brother and I believe the ghost is gone.
News Man: Well that wraps up my interview with Teddy Roosevelt, Archie Roosevelt & Kermit Roosevelt. Live from 106 news and as the Spanish say, Adios.
Teddy, Archie & Kermit: Merry Christmas!
Updated on 12/22/2011 to add: Boo got an A+.
Updated on 12/22/2011 to add: Boo got an A+.
copyright 2011, Melissa, The Betty and Boo Chronicles If you are reading this on a blog or website other than The Betty and Boo Chronicles or via a feedreader, this content has been stolen and used without permission.


text:
Princeton, N.J. and Jamaica Plain, Mass., November 3, 2008 -- Medarex, Inc. (Nasdaq: MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective. The top-line results from the recently completed multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated a statistically significant reduction in recurrences of CDAD when compared with placebo. In the study, 200 patients symptomatic with CDAD receiving standard of care antibiotics (metronidazole or vancomycin) were randomized to receive either intravenous placebo or intravenous administration of a combination of MDX-066 (CDA-1) and MDX-1388 (CDB-1), two fully human antibodies that neutralize C. difficile toxins A and B, respectively.
Consistent with the published literature, the recurrence rate in the placebo-treated group exceeded 20 percent for patients following successful treatment with standard of care antibiotics. In comparison with placebo, MDX-066/MDX-1388 treatment reduced recurrence rates by approximately 70 percent (p=0.0004 on the intent-to-treat population). The antibody combination treatment was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.
The incidence and mortality associated with CDAD has been increasing , with estimates of over 500,000 cases in the United States, and approximately 15,000 deaths caused or contributed by C. difficile. The emergence of a highly virulent epidemic strain that produces much higher levels of toxins A and B has also been associated with morbidity and mortality in younger, healthier, and non-hospitalized patients.
"We are delighted with these dramatic results. CDAD is a growing and serious epidemic, with twenty to fifty percent of hospitalized patients relapsing after receiving antibiotic treatment," said Donna Ambrosino, MD, Executive Director of the MBL and Professor of Pediatrics at UMMS. "The demonstration of significant protection from relapse indicates that treatment with monoclonal antibodies against the toxins could reduce this significant and costly public health problem."
"These results highlight the exquisite specificity of monoclonal antibodies and their important role to save lives," said Howard H. Pien, President and CEO of Medarex. "We believe that the strength of our antibody technology platform for generating potentially important treatment options, such as the C. difficile program antibodies, will continue to shape the future of medicine. Furthermore, Medarex's strategy of proving the utility of potentially promising candidates for development by well-designed and well-executed studies is amply demonstrated."
About Clostridium difficile Acquired Diarrhea (CDAD)
C. difficile is a spore forming bacterium that is common in the environment and can colonize the gastrointestinal (GI) tract. It can be easily spread among hospitalized patients and residents of long term care facilities, but also can be found in otherwise healthy individuals in the community. The origin of disease is believed to develop in the presence of antibiotics administered for other infections, in which the complex microbial make up of the GI tract is altered, and C. difficile spores may germinate, grow, and produce toxins A and B. The toxins cause damage to the GI tract lining in the colon, resulting in severe diarrhea, and may lead to perforations of the colon and/or death. Treatment of severe disease requires administration of additional antibiotics to kill the C. difficile bacteria, but because of the persistence of spores, as well as the difficulty for the intestinal flora to re-normalize in the setting of antibiotics, relapse/recurrence of CDAD is common, and is estimated to occur in 20 percent of cases, with post-therapy recurrence rates as high as 60 percent. Recurrence can be difficult to manage and is a challenging complication of CDAD; however, the use of non-antibiotic based approaches to neutralization of C. difficile toxins may be important options needed to facilitate recovery of the GI flora.
More information on CDAD can be accessed through the following websites:
Centers for Disease Control and Prevention website at www.cdc.gov/ncidod/dhqp/id_Cdiff.html ICAAC/IDSA 2008 website for abstracts at www.icaacidsa2008.org/
About MDX-066 (CDA-1) and MDX-1388 (CDB-1)
MDX-066 (CDA-1) and MDX-1388 (CDB-1) are novel, fully human antibodies that were developed by MBL and Medarex to target and neutralize the effects of toxin A and toxin B, respectively, the toxins produced by the bacterium C. difficile and which are associated with a serious and sometimes deadly form of diarrhea called C. difficile associated diarrhea. Published epidemiologic studies of hospitalized patients at risk for CDAD have shown a positive correlation between detectable levels of antibody in the blood to both toxins A and B and protection from disease or relapse.
In a presentation at the recent joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC, MBL and Medarex presented clinical data that demonstrated the requirement for anti-C. difficile toxin B antibody in addition to anti-C. difficile toxin A antibody for protection in patients with CDAD. These results suggest that the use of antibodies to both toxins may optimally protect against occurrence and are consistent with animal studies conducted by the two companies.
About MBL
The Massachusetts Biologic Laboratories is the only non-profit FDA-licensed manufacturer of vaccines and other biologic products in the United States. MBL produces 30 percent of the U.S. Td vaccine supply. In addition to the C. difficile program, MBL has discovered and developed human monoclonal antibodies for rabies and Hepatitis C, which are expected to enter clinical trials in 2009. The laboratory was established in 1894 and since then the MBL's mission has been to improve public health through applied research, development and production of biologic products. MBL has been a part of the UMass Medical School since 1997.
About UMass Medical School
The University of Massachusetts Medical School is one of the fastest growing academic health centers in the country and has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $193 million in extramural research funding annually. Research dollars enable UMMS scientists to explore human disease from the molecular level to large-scale clinical trials. Basic and clinical research has led to new approaches for diagnosis, treatment and prevention of disease. Visit www.umassmed.edu for additional information.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, the statements in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "may"; "potential"; "preliminary"; "could"; "believe"; or similar statements are forward-looking statements. Medarex disclaims any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with the development of MDX-066 and MDX-1388, unforeseen safety issues resulting from the administration of antibody products in patients, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.
Medarex®, the Medarex logo, UltiMAb® and HuMAb™ are trademarks of Medarex, Inc. All rights are reserved.


text:
Jump to navigation
Lavanya Rajamani is a visiting professor at CPR, where she researches legal issues relating to the environment (in particular climate change), international law, and human rights. She has authored or edited several books on international environmental law, is a frequent contributor to periodicals and academic journals, and has written reports and working papers for organisations including the International Law Association, the World Bank, and the UN Framework Convention on Climate Change (UNFCCC). She also serves on the editorial board of several international academic journals.
Lavanya has worked on and analysed the international climate negotiations since 1998. Among other roles, she has served as a consultant to the UNFCCC Secretariat, as a negotiator for the Alliance of Small Island States, and as a legal adviser to the Chairs of Ad Hoc Working Groups under the FCCC . Lavanya has also advised many government and multilateral agencies, including the Indian Ministry of Environment and Forests, the Danish Ministry of Climate Change, the World Bank, and the UNDP. She also serves as a legal expert in several high-level informal climate dialogues, and has participated in BASIC Expert meetings.
Lavanya has taught at Queens' College, Cambridge, where she was a University Lecturer in Environmental Law, and Fellow and Director of Studies in Law, and at Worcester College, Oxford, where she was a Junior Research Fellow in Public International Law. She has taught or is scheduled to teach international climate change law, international environmental law and human rights at Oxford, the Hague Academy of International Law, University of Aix-Marseille, Osaka Gakuin University, and the University of Bologna. She holds an LLM from Yale, a DPhil and BCL from Oxford, where she was a Rhodes scholar, and a B.A.LL.B. (Honours) from National Law School, Bangalore.


text:
Kids With Asthma Play Hard, Too
In a Shift in Advice, Doctors Tell Patients to Get as Much Exercise as Their Peers
Children with asthma should play hard in gym class and stop worrying they might have an attack that could leave them struggling to breathe, respiratory specialists are now recommending.
Physical activity by people with asthma isn't harmful and might even be helpful to treating the condition, doctors in the field believe. A report published last year in the Cochrane Database Systems Review, a journal that reviews health-care treatments and decision making, looked at 19 previous studies of exercise and asthma and concluded that people with the respiratory condition fared well with physical activity. The studies' results ranged from showing no difference in patients' asthma control to an increase in the number of symptom-free days and a decrease in asthma severity.
Laboratory studies on animals with asthma also have shown that exercise appears to reduce the severity and frequency of attacks, says Timothy Craig, an immunologist and allergist at Pennsylvania State University College of Medicine in Hershey, Pa. The experiments with mice found that exercise calms the activity of inflammatory proteins and peptides in airways that, when stimulated, cause an attack, he says.
"If you have good, controlled asthma, you should be able to exercise," Dr. Craig says.
Fear of physical activity is real for many asthma patients. Exercise can spur an attack, in which the airways get inflamed and lung muscles contract, making it hard for people to catch their breath. If untreated, serious cases can lead to death.
Asthma affects about 9% of children in the U.S. under the age of 17, and for many the condition is lifelong. Overall, more than 25 million Americans of all ages have asthma, representing about 8.4% of the population in 2010, up from 7.3% in 2001, according to data from the Centers for Disease Control and Prevention.
With nearly 1 out of 10 children having asthma, it is important to find ways for them to engage in physical activity, health officials say. Being sedentary increases the risk of obesity. Kids with asthma may struggle socially as well. Being sidelined from gym class or other group activities may make them feel isolated, and other children may see them as fragile and a target for teasing.
When exercise leads to frequent asthma attacks, it is a sign the asthma isn't well controlled and that a better treatment plan is needed, Dr. Craig says. In most of these cases, both the physicians and patients have underestimated the asthma, he says. Patients may then become frustrated and anxious and abandon efforts to exercise, he says.
Celia Vigil, a 12-year-old in Spokane, Wash., avoided strenuous exercise for years for fear of an asthma attack. When she did participate in school sports, she says she usually didn't get very far and often had to be pulled quickly out of a game. An asthma flare-up left her feeling like she couldn't get enough air. "It feels scary," she says. "You don't know when you'll get out of it."
Working Out Safely
Specialists say exercise is important for people with asthma and can even help improve respiratory function. Here are some tips for exercising safely with asthma:
- Make an asthma plan: With a doctor, get your asthma under control. Some people may need to use an inhaler before exercising.
- Warm up: Gradually increasing your heart rate is less likely to trigger an attack than increasing it quickly.
- Sustain activity: Once warmed up, heart rate should remain up for about 30 minutes. For most people, this means a heart rate of 120 to 180 beats per minute depending on your age.
- Sustain activity: Once warmed up, heart rate should remain up for about 30 minutes. For most people, this means a heart rate of 120 to 180 beats per minute depending on your age.
- For people with asthma and allergies, it is best to exercise indoors on highpollen, mold-spore or pollution days.
Source: Timothy Craig, Pennsylvania State University
Two years ago, Celia started seeing a new doctor who talks about the importance of exercise at each visit. She switched to a longer-acting medication, Advair, that better controls her symptoms. And she sometimes takes two puffs on her inhaler before exercising, which she wasn't doing before. Now, Celia says, she is able mostly to keep up with the other kids in gym class. "It's more fun to participate," she says. "I've come really far."
Even when people with asthma have a good treatment plan in place, they need to take extra precautions while exercising, Dr. Craig says. Patients should warm up before walking or jogging, for example, by starting at a slower pace. They also should "warm down" afterward by reducing speed or exertion before stopping completely. Changing one's heart rate gradually appears to lower the risk of an attack, Dr. Craig says.
Children and adolescents with asthma that is under control should aim to achieve the same level of exercise recommended by the CDC as young people without the condition, Dr. Craig says. These recommendations include at least 60 minutes of moderate-intensity aerobic exercise a day, such as brisk walking, plus high intensity activity three times a week.
Guidelines from the National Asthma Education and Prevention Program, issued by the federal National Heart, Lung and Blood Institute, calls for doctors to encourage asthma patients to actively participate in sports and other physical activities.
Still, many parents, sports coaches and doctors who aren't respiratory specialists either don't know that exercise can be helpful for kids with asthma, or they don't routinely talk about exercise with their patients. "I feel there's a lot of education that still needs to take place" in the medical community, says Michele Shaw, a professor at Washington State University College of Nursing who studies exercise in children, with a focus on those with asthma.
Asthma attacks can be brought on by exercise, cold and other triggers, says Shawna Strickland, a respiratory therapist and an associate executive director of the American Association for Respiratory Care. Treatment often includes inhaled corticosteroids, to reduce inflammation, and long- and short-acting beta agonists like albuterol, to relax airway muscles. For some patients, taking a puff or two from an inhaler before exercise can ward off an attack.
Cynthia Vigil, Celia's mother, says the family gradually limited the girl's physical activity when she was younger because of repeated severe asthma attacks. Celia wasn't allowed to go sledding because cold air made her asthma worse; she couldn't play outside with other kids or her two younger sisters, who don't have asthma. "Every one of the messages came out of fear from us," says Ms. Vigil, who works as a counselor at a community college.
It was at a hospital after a severe attack that an emergency room doctor two years ago talked with them about the need to get Celia's asthma under better control. The Vigils followed the doctor's medication advice. They also switched pediatricians.
Ms. Vigil says Celia hasn't had an asthma attack since she's become more active. Last winter, she went snow shoeing with classmates for the first time and she completed a 7-mile walk-run with her family last May. She has also lost weight.
Teachers still call home to ask if it is OK for Celia to participate in certain activities, Ms. Vigil says. She says she still has residual fears about Celia exercising, but she is trying to be encouraging of the girl's interest in joining a sports team in middle school. Celia, who says she feels more included at school, says she is excited to try volleyball this summer to see if it will be her sport.
Write to Shirley S. Wang at email@example.com
Copyright ©2019 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Most Popular Videos
Most Popular Articles
Amazon Has Ceded Control of Its Site. The Result: Thousands of Banned, Unsafe or Mislabeled Products
Billionaire David Koch, Who Used His Wealth to Reshape U.S. Politics, Dies at 79
Latest Round in Trade War Set to Hit U.S. Vehicles, Agriculture Hard
Baby Boomers Are Leaving Behind a Trail of Luxury Ranches
Opinion: Mind Your Manners, Says Edith Wharton


text:
The CVD Epidemiology journal club is a forum for scientific interaction between CVD Epidemiology training program students, collaborating faculty and other students with interest in CVD Epidemiology.
Welcome: Nancy W. Glynn, PhD and Andrea M. Kriska, PhD, MS
Endoscope-Related Infections: Should the Experts in Public Health Be Concerned?
Mohamed H. Yassin, MD, PhD
Associate Professor of Medicine, University of Pittsburgh School of Medicine
Director of Infectious Diseases Division, Medical Director of Infection Control and
Hospital Epidemiologist, UPMC Mercy Hospital
Chair, Quality Committee
Fatigue Mitigation in High Risk Industries: What Does the Evidence Say?
Daniel Patterson, PhD, MPH, MS, NRP, FAEMS
Associate Professor of Emergency Medicine; James O. Page Professor of Emergency Healthcare Worker Safety, Department of Emergency Medicine, University of Pittsburgh
The purpose of the Diabetes Research Journal Club is to discuss current literature in the area of Diabetes, bringing us all up to date with current issues in the field. Each member will be asked to pick a date to briefly (5 minutes) present an article from the journal of their choice, which will be followed by group discussion. However, everyone is invited to brief the group on articles he/she may have found of interest at every meeting.
The Unpredictable Evolution of an Epidemiologist and the Value of a Good Epidemiological Tool Box
Kevin E. Kip, PhD, FAAAS, FAHA
Distinguished USF Health Professor, College of Public Health, Department of Epidemiology and Biostatistics, University of South Florida
The National Personal Protective Technology Laboratory
Edward Sinkule, PhD, MPH, FACSM
Physical Scientist, Centers for Disease Control & Prevention (CDC)/National Institute for Occupational Safety & Health (NIOSH)/National Personal Protective Technology Laboratory (NPPTL)
Utilizing Data to Curb the Opioid Epidemic In Pennsylvania: Practical Application of the PA PDMP
Ashley Parsons, MPH
Program Manager, Pennsylvania Department of Health, Prescription Drug Monitoring Program
The Epidemiology of Brain Resilience in Aging (e-BRAIN) program and the Claude D. Pepper Center at the University of Pittsburgh sponsor the epiBRAIN Journal club, a multidisciplinary Journal Club to explore the application of neuroimaging methods in the context of aging and population studies...
Epi in Action! Student Poster Presentation Symposium
O'Hara Student Center, 2nd floor Ballroom, 12-1:30 PM
Role of Exercise in the Treatment of Geriatric Obesity and Aging-Related Fat Redistribution
Barbara Nicklas, PhD
Professor, Gerontology and Geriatric Medicine, Wake Forest School of Medicine
Title: TBD
Tiffany L. Gary-Webb, PhD, MHS
Associate Professor, Depts. Of Behavioral and Community Health Sciences and Epidemiology
Associate Director, Center for Health Equity, University of Pittsburgh GSPH
Investigating Biliary Tract Cancer Etiology
Jill Koshiol, PHD
Earl Stadtman Investigator, National Cancer Institute
Division of Cancer Epidemiology & Genetics, Infections and Immunoepidemiology Branch
Thomas J. Songer, PhD
Assistant Professor, Dept. of Epidemiology, University of Pittsburgh GSPH
Analytics Careers in Healthcare: UPMC Community HealthChoices
Mary E. Winger, MPH
Analytics Data Integration Developer, UPMC Health Plan, Community HealthChoices
Chendi Cui, PhD
Analytics Data Integration Developer, UPMC Health Plan, Community HealthChoices
Marquis Hawkins, PhD
Assistant Professor, Dept. of Epidemiology, University of Pittsburgh GSPH
Panel Discussion: Nutrition Workshop for Epidemiology
Samaneh Farsijani, PhD, MsC
Postdoctoral Associate, Dept. of Epidemiology, University of Pittsburgh GSPH
Lori Cherok, PhD, RDN, LDN
Assistant Professor and Director, Didactic Program in Dietetics
Interim Director, Nutrition Science Program, Pitt SHRS
Lisa Bodnar, PhD, MPH, RD
Professor and Vice-Chair of Research, Dept. of Epidemiology, University of Pittsburgh GSPH
Pharmacoepidemiology Methods Applied to the Study of the Real-world Use, Safety, and Effectiveness of Oral Anticoagulants
Inma Hernandez, PharmD, PhD
Assistant Professor, Pharmacy and Theraputics; Associate Director, Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh School of Pharmacy
The focus of this journal club will continue to be the presentation of research being conducted by the CVD training grant trainees and faculty collaborating with the URL, as it relates to subclinical cardiovascular disease. This may take the form of practice for overview/comprehensive meetings, preparation for conference talks and/or informal works in progress (WIP) presentations. In addition, we will review published articles related to subclinical cardiovascular disease measure epidemiology and methodology.
Primary Faculty:
Emma Barinas-Mitchell, PhD
Assistant Professor, Department of Epidemiology
Akira Sekikawa, MD, PhD
Associate Professor, Department of Epidemiology
Trevor J. Orchard MD, M Med Sci, FAHA, FACE
Professor, Department of Epidemiology, Medicine & Pediatrics
Andrea Stewart, Journal Club Coordinator
Email: firstname.lastname@example.com
Last Updated On Wednesday, August 16, 2017 by Weller, Alison N
Created On Wednesday, August 16, 2017


text:
Visit Our Lewisville eCig Retail Store
Village Vape & Vapor in Lewisville, TX
Monday - Thursday 11:00AM-8:00 PM
Friday - Saturday 11:00AM-8:00 PM
Sunday 11:00AM-6:00 PM
Village Ecigs
1565 West Main Street #417
Lewisville, TX 75067
Phone: (469) 524-8478
Village E-Cigs was started by frustrated vapers fed up with the myriad of E-Cig stores that endlessly pop up, offering subpar product and unsatisfactory customer service at extremely elevated prices. We don't like seeing a store that looks like a sterile doctors office with a wall of pre-made E-juice and countless blister packaged starter kits. In response to the countless closet-like vapor shops, we opened something more akin to a lounge that is more reminiscent of an old-school cigar shop than an empty waiting room. Our staff is dedicated to customer service. We don't trifle with pushing useless, poorly built products as the best on the market, and we don't want you to ever feel rushed to leave our store. We have ample seating areas, along with free water and coffee so you can feel comfortable coming in and just hanging out for a while. You don't even have to buy anything! We will take time to personally examine your needs and provide the best recommendation for you.
Village E-cigs offers delicious, high quality e-liquid. Our flavors have been created with the finest ingredients available. We have any flavor imaginable, and many more that you may not have imagined! We have carefully mixed each juice to deliver the best flavor experience to the user. We start with a 70% PG/30% VG mixture, and then add the flavorings in front of you at our juice bar. We never pre-mix or pre-bottle our juice, this way we know we can always give you the freshest juice possible. We can also make custom flavors tailored specifically to your taste. Do you want blueberry with lemon and a dash of Pomegranate? We can do that, and anything else you can think of, and if you don't like it, you can bring it back and we'll tweak it for you, if it's not fixable, we'll just give you a new mix free of charge.
Starter Kits
Here at Village E-Cigs, we don't like blister packaged batteries and tanks. These are low quality, and they lack options. We sell our starter kits a-la-carte, piece by piece. This ensures you get the specific color, style, and performance you want. We will walk a beginner through the entire process of setting up their new E-Cig. This includes turning the battery on, setting to the proper voltage, priming the atomizer, filling the tank, and general maintenance and care.
We offer many different choices in Variable Voltage/ Variable Wattage and Mechanical mods. We will take the time to personally assess your needs in a mod, and help you make the perfect decision. We offer anything from a simple VV/VW mod, to the most powerful, cloud making Mechanical mods on the market.
Rebuildable Atomizers
We love rebuilding. From a tricked out Genesis-style atomizer to the humble dripper, we have it all, and we know it all. If you want to get into the premier vaping devices, we'll be with you every step of the way. Pick your RBA of choice, and we'll guide you through the build process, and give you tips. The first build is on us, so you can see how it's done up close and personal, and ask us questions as we do it. Do you want bigger airflow out of your RBA? No problem. We'll bore the hole in your top cap as big as you like, and if you bought it from us, it's on the house. (Please note rebuilding lessons are dependent on how busy the store is.)
Is your mod not working? Maybe you popped the top-cap off and broke a connection, maybe your battery just isn't firing, or perhaps you're sick of a leaky tank. Come in and we'll help you fix the problem to the best of our ability.
Village Ecigs
1565 West Main Street #417
Lewisville, TX 75067
Customer Service Department: (469) 524-8478


text:
Privacy Policy
November 5, 2009
This Privacy Policy (the "Privacy Policy") and other policies which may be posted on this Web Site (the "Site"), such as terms and conditions of use and, if you register for or enroll in any of the services, contests, products or materials (including to make a posting or submission, a donation or a purchase or to subscribe to a publication), provided by American Bible Society, americanbible.org, bibles.com, bibles.org or any of our affiliates on this Site ("American Bible Society" or "ABS"), those registration or enrollment terms (the "Other Agreements"), together govern your use of this Site. ALL OF THE AFORE-MENTIONED GOVERN YOUR USE OF THE SITE EVEN IN THE EVENT YOU ARE ACTING AS AN EMPLOYEE, AGENT, REPRESENTATIVE OR CONTRACTOR ON BEHALF OF ANY OTHER ENTITY OR PERSON. BY USING THE SITE, YOU SIGNIFY YOUR ACCEPTANCE OF THIS PRIVACY POLICY AND OF OUR PROCESSING YOUR PERSONAL DATA IN ACCORDANCE WITH THE TERMS OF THIS PRIVACY POLICY. IF YOU DO NOT AGREE TO THIS PRIVACY POLICY, YOU SHOULD NOT USE THE SITE. YOUR CONTINUED USE OF THE SITE INDICATES TO US THAT YOU HAVE READ AND AGREE WITH OUR PRIVACY POLICY AND THAT YOU ACCEPT ANY CHANGES THERETO, WHETHER OR NOT YOU HAVE ACTUALLY REVIEWED EITHER THE POLICY OR ANY CHANGES THERETO. If you have any questions or concerns regarding this Privacy Policy, please contact: email@example.com.
This Privacy Policy explains how we collect your Personal Data (as defined below) on the Site, how we protect such data, and the choices you have concerning our use of such data. Please read this Privacy Policy carefully. This Privacy Policy represents our current (as of the date first written above) data collection and usage practices. ABS will from time to time review and revise these practices. We will post any changes to this Privacy Policy here. Please refer back to this Privacy Policy on a regular basis. For the purposes of this Privacy Policy, "ABS", "we", "us", and "our" means ABS and its affiliates.
Our policy regulating this Site is simple:
The American Bible Society is committed to protecting your privacy. We allow you to provide as much personal information as you feel comfortable providing. We do not release personal information about you to any third party, except as expressly permitted by you or required by law or court order. We take all reasonable steps to protect your privacy, regardless of how much information you provide.
You control what personal information you provide to us online, and what we can do with such information. You may provide us information about yourself to help us make our Web sites more responsive to you.
We may ask you to supply personal information to us online, including your e-mail address, during a "registration" or an "enrollment" process. Some of this information is given voluntarily, and the word "optional" appears next to the relevant questions. On occasion, we collect additional personal information in optional survey forms, order forms, donation forms and contest registration forms. Demographic information voluntarily provided by you may be combined with site usage reports to create a profile of users and their preferences.
This Privacy Policy applies only to information collected by the Site. We are not responsible for the privacy of any information (i) that you reveal or post in any public forum that may be or in the future become available on the Site (e.g., message board or chat room), (ii) that is available now to the general public through no action or fault of ABS, or (iii) that ABS receives from any third party reasonably known to have a legal right to transmit such information and under no obligation to keep such information confidential. We are also not responsible for the privacy practices of Web Sites that are operated or owned by third parties.
Collection of Personal Data
Personal data is information that identifies you or can be used to identify or contact you, e.g. your name, e-mail address, postal address, or phone number ("Personal Data"). ABS requests Personal Data from you when you register or enroll for use of the Site. The registration or enrollment process requests that you provide your name and e-mail address, and agree to the terms and conditions and, should there be any, the Other Agreements, presented at the time of registration or enrollment. ABS requests additional Personal Data from you when you agree to make a donation or a purchase. Depending on the process, you may be requested that you provide your name, e-mail address, postal address, phone number, credit or bank card or other form of payment, and agree to the terms and conditions and, should there be any, the Other Agreements, presented at the time of donation or purchase. In addition to information collected during registration or enrollment, or when making a donation or a purchase, ABS may collect Personal Data knowingly provided by you in e-mails to the Site or, among other things, online forms, order and registration forms and surveys. Providing this information is always at your option.
In all of these cases, we will collect Personal Data from you only if you voluntarily submit such information to us, and we will only contact you if you permit us to do so. Unless you give us permission to do so, we will not sell, share, license, trade or rent your Personal Data other than as specified in this Privacy Policy. We may, from time to time include on the Site or in e-mails, alerts or other mailings you have agreed to accept from us, advertisements or offers from or information about a sponsor or other third parties interested in serving you ("Third-Party Providers"). This does not and will not mean that ABS endorses any specific materials, information or services available from such Third-Party Providers. Such materials from those Third-Party Providers, regardless of their relationship with us, are provided merely for information purposes and users should make their own judgments and evaluation of any services or products available on any other web sites.
You do not have to provide us with any Personal Data to visit the Site. However, if you choose to withhold requested information, you may not be able to visit all sections or use all features of the Site.
Collection of Monitoring Data and Use of Tracking Tools
In addition to Personal Data, ABS may collect and/or track information that by itself is not used to identify you personally or to contact you, e.g., demographic information, domain names, computer type, browser types, screen resolution, and other anonymous statistical data involving the use of the Site ("Monitoring Data"). We use Monitoring Data to help us understand who uses the Site and to improve and market it and ABS's other web sites.
ABS assigns a random number anonymously to each user for tracking content preferences and traffic patterns. This random number enables us to record how many times users access certain pages, without "naming" who those users are. This random number, called a "cookie," is kept in a file on your computer.
We also log Internet Protocol ("IP") addresses, or the location of your computer on the Internet, for systems administration. These IP addresses are not used to track your session nor are they linked to anything personally identifiable. Cookies and IP addresses ("Tracking Tools") by themselves cannot be used to determine the identity of any user.
To enhance the Internet experience on the Site, ABS may use various Internet technologies such as, without limitation, 'cookies,' 'action tags,' 'web bug,' '.gif tags,' and 'JavaScript'. We believe Tracking Tools and other Internet technologies add value to the user experience, and the information obtained through these technologies is not sold or otherwise made available to third parties by ABS, other than as may from time to time be specified in this Privacy Policy.
Use of Data Collected
We ask for some optional information so we can maintain a further dialogue with you about our new products and services. When you revisit the Site, ABS may recognize you by a Tracking Tool and customize your experience accordingly. For example, once you have completed the registration or enrollment process, a cookie will be used to avoid having you register again. You may decline Internet cookies, if any, by using the appropriate feature of your Web browser software, if available. If cookies are disabled, however, all features of the Site may not operate as intended. Information about the procedure you are required to follow in order to disable cookies can be found on your Internet browser provider's Web Site.
ABS may use Personal Data and Monitoring Data it collects for editorial and feedback purposes, marketing and promotion, statistical analysis of users' behavior, product development, delivering products and services, providing customer support, customizing and improving the content and layout of the Site or other web sites of ABS, completing business transactions, administering individual accounts and meeting government regulatory requirements. Monitoring Data may be used for internal or external purposes such as researching and identifying market segments and needs. ABS may disclose your Personal Data to unaffiliated third parties if we believe in good faith that such disclosure is necessary (a) to comply with applicable laws, rules, or regulations, or to preserve ABS's legal rights in the Site's content, whether the same arises from contract or through force of law; (b) to provide you with any services, information, special offers, promotions or products you requested or consented to and to allow us to perform other activities related to such services and products; or (c) to operate this Site and other of ABS' systems properly. ABS may also share your Personal Data with a Third-Party Provider, but only if you have first told us we may. You may also share your Personal Data directly with Third-Party Providers who you contact through the Site.
You should be aware that, once you give such permission for ABS to share, or once you have shared, your Personal Data with a Third-Party Provider, ABS is not responsible for any further use or disclosure of your Personal Data by Third-Party Providers; such use or disclosure is governed by the Third-Party Providers' privacy policies.
In each e-mail we may send you, you will have the option to unsubscribe and not receive future e-mail from us. We cannot make such assurances on behalf of any Third-Party Provider. Please review our Opt-Out Policy (below) for how to avoid receiving further e-mails.
If at any time you want to be removed from our database or to "opt-out" of receiving further communications ("Opt-Out Policy"), simply tell us what want to be opted out of when you contact us in any of the following ways:
- By e-mail at: firstname.lastname@example.com. Please mark the subject heading of your e-mail "Unsubscribe"
- By letter sent to us at:
American Bible Society
1865 Broadway
New York, NY 10023
Attn: Webmaster—Unsubscribe
Please note that ABS makes no representation regarding the length of time this process may take, only that we will perform the update as soon as reasonably practicable.
The American Bible Society is committed to making your visit with us an enriching, empowering and informative experience. We will honor our pledge to protect your privacy.
ABS reserves the right to transfer Personal Data and Monitoring Data it collects to successors to the relevant portion of any of ABS' businesses, or to independent contractors it engages to assist with or perform on ABS' behalf any of the foregoing activities. Also, if ABS' assets are subject to a claim in bankruptcy, Personal Data and Monitoring Data may be an asset subject to the claims of a trustee in bankruptcy and may be available to ABS' creditors. In addition, ABS reserves the right to use Personal Data to contact you regarding your account status and changes to this Privacy Policy, the terms and conditions of use, Other Agreements (if applicable) or any other policies, agreements or transactions relevant to your use of the Site. ABS will take reasonable steps to maintain the integrity of the collected data so that it is reliable and appropriate for the foregoing uses.
Your Choices Regarding Personal Data Collection and Use
You may "opt-in" to having ABS use your Personal Data to send promotional or other correspondence to you by checking the appropriate box when you register or enroll, or by contacting ABS via e-mail at the address above. You may modify, correct, change or update Personal Data that ABS has collected via the Site or request that your Personal Data be removed from ABS' database by contacting ABS pursuant to the Opt-Out Policy indicated above. If you have made donations to or purchases from or otherwise registered with us in the past, you may also request that your Personal Data be removed from ABS' database by contacting ABS via e-mail at email@example.com. In any instance, our removal of such information may require you to register again with ABS in the event you later wish full access to the Site.
You should be aware that it may not be technologically possible to remove or verify each and every record of information you have provided to us from our system. The need to back-up our systems to protect information from inadvertent loss means that a copy of your Personal Data may exist in archived systems. However, after receiving your request, all Personal Data stored in databases we actively use and other readily searchable media will be updated, corrected, changed, deleted or confirmed to you, as appropriate, as soon as reasonably practicable.
The Site may contain links to other Internet Web Sites maintained by third parties ("Other Sites"), either as a hyperlink or through a direct data feed accessed by you. ABS does not endorse, and is not responsible for, the privacy practices or the content of these Web Sites. You should review the applicable privacy policies in connection with your use of such third party Web Sites.
Security Measures
ABS has established reasonable precautions to protect collected Personal Data from loss, misuse, unauthorized access, disclosure, alteration or destruction, which include contractual, administrative, physical, and technical steps. Technical measures include use of firewall protection and encryption technology where appropriate. Although ABS takes reasonable precautions to assess the reliability of such technology, it relies on the statements of the vendors of those products and services as part of its security evaluation. BY USING THE SITE, YOU ACKNOWLEDGE AND CONSENT TO THE FACT THAT ABS SHALL HAVE NO LIABILITY FOR FAILURES OF SUCH PRODUCTS AND SERVICES AND THAT YOU SHALL HAVE RECOURSE SOLELY AGAINST THE MANUFACTURERS OR VENDORS THEREOF. Please note that while ABS has endeavored to create a secure and reliable site for users, the confidentiality of any communication or material transmitted to/from ABS or the Site or via e-mail cannot be guaranteed.
Export of Personal Data
By using the Site, you acknowledge and consent to the fact that Personal Data provided by you or collected by us through your use of the Site is stored and processed by us in the United States where data protection laws may not afford the same level of protection as those of the country in which you are located (this is the case for users located in the European Economic Area ("EEA")). You also acknowledge and consent to the fact that we may, at our discretion, store and process such data in other countries (including countries outside the EEA) where data protection laws or law enforcement systems, policies or professionals may not afford the same level of protection as those of the country in which you are located.
Privacy Protections for Children Using the Internet
Protecting children's privacy is important to us. For that reason, we do not collect or maintain information on our Site from those we actually know are under the age of 13, nor is any part of our Site targeted to attract anyone under 13. We request that all visitors to our Site who are under 13 not disclose or provide any personally identifiable information. If we discover that a child under 13 has provided us with personally identifiable information, we will delete that child's personally identifiable information from our records.
Contact Information for ABS
Questions or concerns regarding ABS's data protection practices should be addressed to: firstname.lastname@example.com. If you choose to contact ABS via e-mail about this policy, please mark the subject heading of your e-mail "Privacy Inquiry."
We shall keep a copy of this Privacy Policy and if, at any time, you would like to see a copy of it, you should write to the address above.


text:
- Read the latest issue of the ProbesOnline E-Newsletter.
- flow cytometry │live cell cycle analysis │ Vybrant® DyeCycle™ Ruby Stain
- flow cytometry │dead cell discrimination │SYTOX® AADvanced™ Dead Cell Stain
- cellular imaging │high-content screening │ HCS NuclearMask™ Deep Red stain
- cellular imaging │high-content screening │ HCS LIVE/DEAD® Green Kit
- cell signaling | primary antibodies | phosphospecific and total antibodies
- protein labeling chemistry │ Click-iT® technology │ Click-iT® Protein Reaction Buffer Kit
- flow cytometry │control reagents │ AbC™ anti-Mouse Bead Kit
- proven performers
- buzzworthy
- the view
- on the web
- in the field
what it is
Vybrant® DyeCycle™ Ruby Stain is a near-infrared emission stain for DNA content analysis, enabling live cell cycle analysis with limited cytotoxicity.
how it works
Vybrant® DyeCycle™ Ruby Stain is a dye that penetrates the cell membrane of intact cells. Once inside the cells, the dye binds covalently to the DNA in the nucleus. Staining is simple—suspended cells are incubated with Vybrant® DyeCycle™ Ruby Stain and fluorescence is measured directly. No additional treatment or centrifugation is required. This dye takes advantage of the commonly available 488 nm and 633/635 nm excitation sources with emission >670 nm, leaving common blue laser channels open for other studies. And unlike DRAQ5, Vybrant® DyeCycle™ Ruby Stain does not kill the analyzed cells, offering the possibility of cell sorting based on DNA content.
what it offers
- live cell cycle analysis
- limited cell toxicity offers cell sorting potential
- compatible with any flow cytometer
|Excitation and emission spectra of Vybrant® DyeCycle™ Ruby Stain.
|Cat. no.
|Vybrant® DyeCycle™ Ruby Stain
|400 assays
|Vybrant® DyeCycle™ Ruby Stain
|100 assays
what it is
The SYTOX® AADvanced™ Dead Cell Stain Kit includes a new high-affinity nucleic acid stain that selectively penetrates cells with compromised plasma membranes. The stain can also be used with fixed cells for DNA content cell cycle analysis.
how it works
SYTOX® AADvanced™ Dead Cell stain is spectrally similar to 7-AAD, but with rapid uptake kinetics. After brief incubation with SYTOX® AADvanced™ stain, the nucleic acids of dead cells fluoresce bright red-orange when excited with 488 nm blue laser light. These properties, combined with its >500-fold fluorescence enhancement upon nucleic acid binding, make the SYTOX® AADvanced™ stain a simple and quantitative single-step dead-cell indicator. The DNA content histogram of fixed cells gives lower CVs than 7-AAD, making it ideal for use in multicolor applications requiring DNA content measurement.
what it offers
- fast labeling of dead cells—only 5 minutes to results
- efficient cell penetration—better separation of live and dead cells than 7-AAD
- compatibility with multicolor applications—minimal compensation with the PE channel
- tighter CVs for more accurate DNA content measurement
|Discrimination of dead cells using the SYTOX® AADvanced™ Dead Cell Stain Kit. A mixture of heat-killed and untreated Jurkat cells were stained with 1 µM of SYTOX® AADvanced™ Dead Cell stain solution for 5 min. Cells were analyzed on a flow cytometer equipped with a 488 nm laser and a 695/40 nm bandpass filter. Live cells are easily distinguished from the dead cell population.
|DNA content analysis using the SYTOX® AADvanced™ Dead Cell Stain Kit. HL-60 human promyeloblastic leukemia cells were alcohol fixed and then suspended in 0.1% Triton X/PBS/1% BSA. Cells were stained with 1 µM of SYTOX® AADvanced™ Dead Cell stain solution with the addition of RNase A for 30 min at room temperature. Cells were analyzed on a flow cytometer equipped with a 488 nm laser and a 695/40 nm bandpass filter.
|Cat. no.
|SYTOX® AADvanced™ Dead Cell Stain Kit
|100 assays
|SYTOX® AADvanced™ Dead Cell Stain Kit
|500 assays
Accurate cell identification with HCS NuclearMask™ Deep Red stain
what it is
The versatile HCS NuclearMask™ Deep Red nuclear stain enables analysis of DNA content and cell demarcation of live and formaldehyde-fixed cells, using high-content imaging and analysis platforms.
how it works
In image-based high-content screening (HCS) assays, cell or object identification is the first step of the automated image acquisition and analysis process. For many software algorithms, the cell identification process begins with the detection of fluorescent stained nuclei. Using the position of the stained nucleus as a guide, the software then extrapolates to mark the probable position of the cytoplasmic region. With its near-infrared excitation/emission of 638/686 nm when bound to DNA, HCS NuclearMask™ Deep Red stain is ideal for cell demarcation and DNA content analysis, and can be easily discriminated from blue and green fluorophores in multiparametric studies.
- proven performance—validated for image segmentation on HCS platforms
- selection—alternative to blue-fluorescent Hoechst for multiplexing flexibility
- simple, user-friendly protocol
|Multiparametric analysis of nocodazole-induced mitotic arrest in A549 cells. Nuclear segmentation and DNA content measurements were performed using HCS NuclearMask™ Deep Red stain. The strong increase in both phospho-H3 and DNA is indicative of mitotic cells. The images were quantitated using the Cellomics® ArrayScan® VTI platform (Thermo Scientific).
|Cat. no.
|HCS NuclearMask™ Deep Red stain
|400 µl
what it is
The HCS LIVE/DEAD® Green Kit provides an ideal means to measure cell viability for high-content imaging studies.
how it works
This kit includes Image-iT® DEAD Green™ viability stain for discrimination of dead cells and HCS NuclearMask™ Deep Red stain or Hoechst 33342 for total cell demarcation. Image-iT® DEAD Green™ viability stain is impermeant to healthy cells, but gains entrance when the plasma membrane integrity of cells is compromised by drugs, test compounds, or other agents. Unlike other viability stains, the Image-iT® DEAD Green™ viability stain is amenable to fixation and permeabilization.
what it offers
- comprehensive analysis of cell health and toxicity— simultaneous detection of prelethal and lethal aspects of cellular stress and viability
- content-rich results—includes reagents compatible with fixation and detergent-based permeabilization, enabling the addition of other antibody-based parameters to the assay
- simple, user-friendly protocol
|Dose response for valinomycin in HeLa cells using the HCS LIVE/DEAD® Green Kit. HeLa cells were treated with valinomycin at final concentrations between 0 to 120 μM and incubated for 24 hr at 37°C. Imaging and analysis were performed using a 10x objective and the Compartmental Analysis BioApplication with the Thermo Scientific Cellomics® ArrayScan® VTI platform.
|Cat. no.
|HCS LIVE/DEAD® Green Kit
|1 kit
what they are
This month we are launching a diverse array of new antibodies covering a broad spectrum of research areas, including nuclear receptors/transcription factors, organelles/cell structure, protein translation/ubiquitination, ion channels, neurobiology/neurodegeneration, kinase/phosphatase proteins, and cell cycle/apoptosis.
how they work
We are actively expanding our collection of primary antibodies to enable analysis of key targets in normal and disease states, including cardiovascular disease, cancer, inflammation, neurodegenerative diseases, and diabetes. Sixteen new antibodies are available for targets including Stargazin, Aquaporin 2, NMDA, Parkin, and various members of the GABA family. Many of these markers play important roles in signaling pathways leading toward neurodegeneration.
what they offer
- confidence—all phosphorylation site specificities have been verified with peptide competition
- performance—robust antibodies are validated for multiple applications
- selection—a large menu of unique specificities, with a wide range of targets and modification sites
|Human SH-SY5Y cells stained with mouse anti-fibrillarin, showing prominent blue nucleolar staining. The nuclei are stained with blue-fluorescent DAPI. Cells are also stained with a fluorescently labeled chicken antibody to neurofilament NF-H (red fluorescence).
|Western blot of a HeLa cell lysate showing specific immunolabeling of the ~34 kDa fibrillarin protein.
| Species
|Cat. no.
|Mouse anti-IL-8 (guinea pig)
|100 μg
|Hu, GP
|Mouse anti-TNF-α (guinea pig)
|500 μg
|Fibrillarin (Nop1p), Mouse Monoclonal Antibody
|100 μl
|Hu, R, Dr
|Tubulin, beta III, Mouse Monoclonal Antibody
|100 μl
|R, B, Hu, Ms
|Ubiquitin C-terminal Hydrolase 1 (UCHL1), Mouse Monoclonal Antibody
|100 μl
|Stargazin, Rabbit Polyclonal Antibody
|100 μl
|GABAA , α3-Subunit, Rabbit Polyclonal Antibody
|100 μl
|R, Hu
|GABA Transporter (GAT) 2, Rabbit Polyclonal Antibody
|100 μl
|GABA Transporter (GAT) 3, Rabbit Polyclonal Antibody
|100 μl
|Aquaporin 2 [pS261], Phospho Antibody
|100 μl
|GABAB [pS783], R2-Subunit, Phospho Antibody
|100 μl
|GABAB [pS923], R1-Subunit, Phospho Antibody
|100 μl
|NMDA Receptor NR2B Subunit [pS1480], Phospho Antibody
|100 μl
|MEK5 [pSpT311/315], Phospho Antibody
|100 μl
|PAK-1,2,3 [pT402], Phospho Antibody
|100 μl
|Parkin [pS101], Phospho Antibody
|100 μl
|Parkin [pS378], Phospho Antibody
|100 μl
|Polo-Like Kinase 1 [pS210], Phospho Antibody
|100 μl
|Hu, R
|NMDA NR2A, N-terminus, Rabbit Polyclonal Antibody
|100 μl
|* ICC = immunocytochemistry, IF = immunofluorescence, IHC = immunohistochemistry, WB = western blot.
† B = bovine, Dr = Drosophila, GP = guinea pig, Hu = human, Ms = mouse, R = rat.
For a list of additional phosphorylation site–specific antibodies, visit www.invitrogen.com/pssa.
To browse antibodies by specificity or application, visit www.invitrogen.com/antibodies.
what it is
The Click-iT® Protein Reaction Buffer Kit provides researchers with proteins labeled with a terminal azide or alkyne and the corresponding click detection reagent with the power to "click" these two moieties together. Each kit includes sufficient materials to perform 25 reactions for subsequent analysis of the protein by gel electrophoresis, western blot, or mass spectrometry.
how it works
Click chemistry describes a powerful new class of chemical reactions that use biologically unique moieties to label and detect proteins of interest using a simple, two-step procedure. In the first step, an azide- or alkyne-containing biomolecule is fed to cells and then actively incorporated into the protein. Unlike other labels, the azide and alkyne tags are small enough that tagged biomolecules (e.g., sugars and amino acids) are acceptable substrates for the enzymes that incorporate these building blocks into proteins. A subsequent detection step uses the chemoselective ligation or "click" reaction between an azide and alkyne, where the modified protein is detected with a corresponding azide- or alkyne-containing dye or hapten for subsequent analysis by standard biochemistry techniques such as gel electrophoresis or western blotting.
what it offers
- pioneering biological insights—expose previously undiscovered and elusive posttranslational modifications
- exquisite sensitivity—detect femtomole protein levels
- context-rich results—perform multiplexed analyses in the same gel or blot
|Cat. no.
|Click-iT® Protein Reaction Buffer Kit
|1 kit
what it is
The AbC™ Anti-Mouse Bead Kit provides a consistent, accurate, and easy-to-use technique
for setting flow cytometry compensation when using fluorochrome-conjugated mouse
antibodies. The kit contains two types of specially modified polystyrene microspheres: the
AbC™ capture beads, which bind all isotypes of mouse immunoglobulin, and negative beads with no antibody-binding capacity.
how it works
After incubation with the same fluorochrome-conjugated mouse antibody that will be used for cell staining, the beads are washed in staining buffer, a drop containing negative control beads is added if required, and the beads are resuspended and analyzed by flow cytometry. The two components provide distinct positive and negative populations of beads that can be used to set compensation.
what it offers
- fast and simple bead-based compensation
- elimination of the need to use precious samples for setting compensation
- accurate and consistent results—highest reactivity to different subclasses of mouse immunoglobulin
- confidence in your results—avoid inconsistencies due to variations in antigen expression
|Cat. no.
|AbC™ Anti-Mouse Bead Kit
|1 kit
Expression of the intrinsically fluorescent green-fluorescent protein (GFP) from the jellyfish Aequorea victoria has become a highly trusted method for following gene expression and protein localization. Invitrogen continues to offer a comprehensive selection of anti-GFP antibodies. The workhorse of our offering is our rabbit polyclonal antibody raised against GFP purified directly from A. victoria. This anti-GFP antibody, available as a complete serum or as an IgG fraction, facilitates the detection of native GFP, recombinant GFP, and GFP-fusion proteins by immunofluorescence, western blot analysis, and immunoprecipitation. Direct conjugates made from the IgG fraction, using our best Alexa Fluor® dyes, are also available. Additional options for your research include two mouse monoclonal antibodies and a chicken IgY fraction.
|HeLa cell transfected with pShooter pCMV/myc/mito/GFP, then fixed and permeabilized. Green-fluorescent protein (GFP) localized in the mitochondria was labeled with mouse IgG2a anti-GFP antibody (A11120) and detected with orange-fluorescent Alexa Fluor® 555 goat anti–mouse IgG antibody (A21422), which colocalized with the dim GFP fluorescence. F-actin was labeled with green-fluorescent Alexa Fluor® 488 phalloidin (A12379), and the nucleus was stained with blue-fluorescent DAPI (D1306, D3571, D21490). The sample was mounted using ProLong® Gold antifade reagent (P36930). Some GFP fluorescence is retained in the mitochondria after fixation (top), but immunolabeling and detection greatly improve visualization (bottom).
|Cat. no.
|Anti-GFP, rabbit serum (polyclonal)
|100 μl
|Anti-GFP, rabbit IgG fraction
|100 μl
|Anti-GFP, rabbit IgG fraction, biotin-XX conjugate
|100 μl
|Anti-GFP, rabbit IgG fraction, HRP conjugate
|100 μl
|Anti-GFP, rabbit IgG fraction, Alexa Fluor® 488 conjugate
|100 μl
|Anti-GFP, rabbit IgG fraction, Alexa Fluor® 594 conjugate
|100 μl
|Anti-GFP, rabbit IgG fraction, Alexa Fluor® 555 conjugate
|100 μl
|Anti-GFP, rabbit IgG fraction, Alexa Fluor® 647 conjugate
|100 μl
|Anti-GFP, mouse IgG2a, monoclonal 3E6
|100 μg
|Anti-GFP, mouse IgG1, monoclonal 11E5
|100 μg
|Anti-GFP, chicken IgY fraction
|100 μl
|Anti-GFP, chicken IgY fraction, biotin-XX conjugate
|100 μl
Migueles, S.A. et al. (2008) Immunity 29:1009–1021.
What is the biochemical basis of natural HIV resistance? Long-term nonprogressors (LTNPs, or elite controllers) are rare individuals who manifest a natural control over HIV replication. LTNPs have demonstrated the ability to maintain stable CD4+ T cell counts and low viral loads over the course of many years following their infection with HIV, even in the absence of antiretroviral drug therapy. While several studies have suggested a role for HIV-specific CD8+ T cells in the successful control of HIV replication in LTNPs, details of their role remain poorly understood. In the present study, Migueles and colleagues investigated the cytotoxicity of HIV-specific CD8+ T cells from LTNPs; they observed that these cells exhibit much greater cytotoxic capacity than those from progressors (i.e., non-resistant individuals). Cytotoxicity assays using the LIVE/DEAD® Fixable Violet Stain Kit linked this enhanced cytotoxic capacity to the granzyme B content of lytic granules. Further experiments showed that the lytic power of progressor CD8+ T cells could be re-established by treating them with phorbol ester and calcium ionophore, an effect possibly mediated by an NFAT (nuclear factor of activated T cells)-related mechanism. The authors suggest that future therapeutic regimens for HIV could involve agents that increase the cytotoxic capacity of HIV-specific CD8+ T cells.
|Find the tools you need for high-content screening
High-content screening (HCS) is a marriage between instrumentation, reagents, and informatics that brings fluorescent microscopy into the higher-throughput domain. Since this new approach was introduced in the late 1990s, Invitrogen Molecular Probes® products have been instrumental for the growth of this field. We recently introduced a portfolio of validated HCS kits for toxicology and cytotoxicity screening. These kits add to our already extensive line of tools and kits for HCS platforms including our LipidTOX™ reagents and CellMask™ stains.
You can find out more about all our HCS reagents at our newly updated HCS central page at www.invitrogen.com/hcs.
|New MAPK signaling pathway web page
Whether your MAPK pathway research requires basic research tools, cell-based assays, or comprehensive screening services, Invitrogen has solutions for you. Empower your research today using our comprehensive portfolio of products and services to investigate the MAPK pathway—everything from high-quality reagents for basic research and assay development to validated biochemical and cell-based assays, as well as world-class profiling and screening services.
View our portfolio of reagents for MAPK signaling at www.invitrogen.com/mapk.
|Free online technical webinars
You are invited to join us for a series of biweekly technical webinars from the comfort of your desk. The webinars will initially focus on imaging-related applications, but we welcome your feedback for additional topics throughout the course of the year. Upcoming topics will be announced each month via email.
Presentations will last approximately 45 minutes, followed by 15 minutes for live Q&A.
Missed our February webinars? Find them at the links below:
- Fluorescent Imaging in Cell Biology (February 3, 2009)
- Accessorize Your Imaging (February 17, 2009)
Molecular Probes® The Handbook
©2009 Molecular Probes, Inc. Visit our website for a complete listing of legal notices and trademark attributions. Feel free to distribute ProbesOnline to friends and colleagues, but please keep this copyright statement intact.


text:
June 26, 1899
[Page 40]
Sunday (last) night we went ashore + saw two prospectors outfit, + a loon. This morning, in Port Wells, we went up some unexplored glacier wilds and saw some fine things. A small party of us found a colony of Arctic terns and short-billed gulls. I saw my first Oystercatchers, + got them. There were two; [male] + [female], which gave me a good run. Kittlitz's Murrelets were secured, and Fisher got a [Page 41] red-poll and a [male] willow ptarmigan, and a wandering tattler.
The birds of this bag were, as observed by Fisher and myself,
Short Billed Gull Dwarf Hermit Thrush
Arctic Tern Townsend's Sparrow
Wandering Tattler Willow Ptarmigan
The terns here seemed to have turned the tables on the gulls, chasing them fiercely, + the gulls turned tail every time.
Ned Trudeau + Dr. Morris stopped off for a time in the lower bay and came aboard with some surf scoters and alb. W.S. and 3 wandering Tattlers, and Cole, from another stop, got a fine [male] pinicola
At Orca a few days ago, we failed to see any bird except a couple of pacific fulmars + Kittwakes, barn swallows, and dwarf hermit thrushes, + these were not very common except Rissa.
Dr. Merriam got a [female] Canada Goose at Bone Pt. Orca Sound, and I got a fish crow (caurinus) and saw a pair of king fishers - also at a little boggy pool saw foot prints of crows (c.c) and a goose and some [Page 42] small corvine foot, probably Stellar's Jay. Heard what I took for juncos in the spruces, and Keeler heard the Savannah Sp.
Similar Birds
in Fuertes
Clear Illustration


text:
Confederations Cup 2013: Spain thrash Tahiti 10-0
Spain secured an emphatic 10-0 win over Tahiti, who were involved in an international competition for the first time in their history.
The Spanish attack was brilliant as the trio of David Villa, Fernando Torres and David Silva put on a sizzling display together.
Torres found the net four times and Barcelona star Villa scored a hat-trick, too. Silva netted a brace, while Chelsea's Juan Mata also got on the scoresheet.
Torres had a wonderful match and showed pace, determination and superb finishing abilities - despite being up against Tahiti, who are the tournament underdogs. He also had time to miss a penalty as his shot hit the bar and deflected away.
This victory, which is Spain's biggest victory in a major international competition, would surely give the reigning world champions enough momentum to go on and add one of the few trophies currently absent from their trophy cabinet.
Also, the performances from Torres and Villa will act as a confidence-booster for them, and give coach Vicente Del Bosque a selection headache for the rest of the tournament.
Visit the official Confederations Cup 2013 Facebook page: https://www.facebook.com/fifaconfederationscupbrazil2013
Write for GiveMeSport! Sign-up to the GMS Writing Academy here: http://bit.ly/12evFlH
DISCLAIMER: This article has been written by a member of the GiveMeSport Writing Academy and does not represent the views of GiveMeSport.com or SportsNewMedia. The views and opinions expressed are solely that of the author credited at the top of this article. GiveMeSport.com and SportsNewMedia do not take any responsibility for the content of its contributors.News Now - Sport News


text:
Suarez family in tears after Manchester 'bite' taunt
Liverpool forward Luis Suarez says his family were left 'on the brink of tears' after fans in Manchester pretended to bite him when he was asked to pose for a photo.
The controversial Uruguyan is angling for a move away from Liverpool after claiming he is being hounded out of the country by the English media.
Suarez was the subject of increased press attention following his 10-game ban for biting Chelsea defender Branislav Ivanovic, which means he will miss the start of next season.
The Anfield striker has been linked with a move to Real Madrid in recent weeks, and has hinted he is after a move to the Bernabeu.
Suarez highlighted an incident in Manchester which he feels demonstrates why he needs to leave Liverpool and the Premier League.
"About a week ago I was walking in a shopping centre near Manchester and three or four guys asked me for a photo," he told RR Gol.
"While we were posing for it my wife said to me "Luis, get out of the photo". She noticed they were making biting gestures. I was with my wife and my daughter. Things like that get on your nerves. My wife was on the brink of tears and the blokes ran off laughing. You get tired of stuff like that."
Suarez's ban for racially abusing Manchester United's Patrice Evra has also dogged his time in England, and he believes his suspension was disproportionate given that John Terry was banned for four games by the FA for a similar incident.
"Without any proof they gave me an eight-match ban, but with Terry, where they had proof, lip-readers, they gave him four, I'm South American and I think that's the root of all of this," Suarez claimed.
Amidst rumours of a big-money move to Real Madrid - which Liverpool say they will not consider - Suarez concedes even his love for the Merseyside club is not strong enough to make him stay.
"Liverpool is a club that I dreamt about playing for as a boy. I have been with great players there, they know me and I would love to continue for many more years at Liverpool. The stadium is spectacular, the fans are phenomenal: people with tattoos of me, things that I could never have imagined.
"After the [Evra] suspension people would come up to me, this is something that really touched me and they would say: "Luis forget everything and stay."
"But I can't forget as it was something that I had to suffer, that my family had to suffer and away from football I have a family to support and who are hurt by these things."News Now - Sport News